Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mind-Controlled therapy: could brain signals help Parkinson's patients move better?

NCT ID NCT06690931

Disease control Sponsor: g.tec medical engineering GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether a brain-computer interface (BCI) can help people with Parkinson's disease improve their motor skills. Participants wear an EEG cap that reads brain activity while they imagine moving their legs. The system then provides feedback through electrical stimulation and virtual reality. Researchers will compare this approach to standard therapy without the brain monitoring. The goal is to see if the BCI method leads to greater improvements in walking and movement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Brain-computer interface (BCI) neurofeedback therapy using the recoveriX PRO system, which combines motor imagery, functional electrical stimulation (FES), and virtual reality (VR) feedback.
What this could lead to
If it works, this could offer a non-drug rehabilitation approach to improve walking and movement in Parkinson's disease, potentially easing daily life for patients.
What could go wrong
This is a small early-stage trial with only 30 participants, so results may not apply broadly. The therapy requires many sessions and may not produce lasting improvement for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of PD * HY stage between 1 to 3 * Age between 40 - 80 years old * Ability to walk independently * Stable medication usage * Stable neurological condition * Able to sign the informed consent. * Able to follow the study protocol. Exclusion Criteria: * Other neurological diseases * Severe depression * Uncontrolled diabetes * Concomitant severe neurologic, cardiopulmonary, or orthopedic disorders * Debilitating conditions or vision impairment that would impede full participation in the study. * Unpredictable motor fluctuations * Pregnant * Active or passive implanted medical devices such as pacemakers which do not allow the use of FES. * Implanted metallic fragments in the upper and lower extremities which can limit the use of FES. * Under the influence of anesthesia or similar medication. * With fractures or lesions in the upper and lower extremities. * Inadequate control of a BCI system.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • g.tec medical engineering GmbH

    Schiedlberg, Upper Austria, 4521, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.